Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Exercise training · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Exercise training | BEHAVIORAL | - |
Inclusion Criteria: * diagnosis of prostate cancer * receiving docetaxel-based chemotherapy at the CCI * age 18 years or over * approval of oncologist * informed written consent Exclusion Criteria: * life expectancy less than 6 months * Karnofsky performance score less than 70 * contraindications...
Exercise Training, Usual Care is an investigational intervention being studied in oncology for conditions including colonic neoplasms and prostatic neoplasms. It is being evaluated in patients with prostate cancer receiving docetaxel-based chemotherapy for hormone refractory disease, as well as in colon cancer survivors, with a focus on health-related fitness.
Exercise Training, Usual Care is being developed by Avalon GloboCare Corp., a company traded under the ticker ALBT. The intervention is currently in Phase 2 clinical development for oncology indications.
Exercise Training, Usual Care is in Phase 2 clinical development. It is an investigational intervention, not yet approved by regulatory authorities, and is being studied in completed clinical trials for prostate and colon cancer patient populations.
Exercise Training, Usual Care has been studied in two completed Phase 2 trials: NCT00271687, a pilot study of exercise in patients with docetaxel-based chemotherapy for hormone refractory prostate cancer, and NCT00813540, examining the effects of exercise training on health-related fitness of colon cancer survivors.
Exercise Training, Usual Care refers to a specific investigational intervention being evaluated in clinical trials. It is not identified as having alternative names in the available information, and it is distinct from standard care or usual care alone.